Approval of brexucabtagene autoleucel for adults with relapsed and refractory acute lymphocytic leukemia
Cette étude analyse les données de l'essai ayant conduit la "Food and Drug Administration" à autoriser l'utilisation du brexucabtagène autoleucel pour traiter les patients adultes atteints d'une leucémie lymphoïde aiguë réfractaire ou récidivante
In October 2021, brexucabtagene autoleucel became the first anti-CD19 chimeric antigen receptor T cell product to receive approval from the US Food and Drug Administration to treat adults with relapsed and refractory B cell acute lymphoblastic leukemia (r/r ALL). The approval is based on results from the Zuma-3 trial and significantly widens treatment options for this patient population. In this article we will review outcomes from this study and its implications.
Blood 2022